The global burden of gout is set to expand dramatically over the next quarter-century, with prevalence projected to rise significantly due to aging populations, obesity, and lifestyle factors. In the United States alone, over 9 million people have already been diagnosed with the painful chronic disease, and an even larger pool of 44 million people have uric acid levels above the normal range, putting them at risk. While existing oral xanthine oxidase inhibitors are the standard of care, they carry boxed warnings for cardiovascular risk, and roughly 3% to 5% of patients cannot tolerate them. Other side effects include severe gastrointestinal issues, kidney toxicity, and paradoxical flare-ups that discourage adherence.
XORTX Therapeutics Inc. (NASDAQ: XRTX), a late-stage clinical pharmaceutical company, believes it has a solution in XORLO™, a proprietary formulation of oxypurinol. According to XORTX, XORLO overcomes the historically poor oral absorption of oxypurinol by using a liposomal delivery system that enables high bioavailability and rapid absorption. This allows uric acid lowering at substantially lower total daily doses, minimizing toxic-level exposure and the severe gastrointestinal side effects associated with high-dose traditional therapies.
The company is making tangible progress toward commercialization. It recently announcing the launch of drug material and tablet manufacturing to support its planned two-part clinical study, XRX-OXY-102. That trial is advancing based on positive prior clinical results and discussions with the FDA. Contract production of pure oxypurinol, the active ingredient in XORLO, has begun using XORTX’s proprietary synthetic pathway, and the company is now working with its manufacturing partner toward commercial drug batches.
Regulatory milestones are also in sight. XORTX is working toward a new drug application submission to the FDA for XORLO. The company has prepared a new Investigational New Drug (IND) application for submission in the fourth quarter of 2026, describing its clinical development plan. If the two-part trial completes successfully, XORTX intends to request a pre-NDA meeting and prepare an NDA submission while simultaneously engaging in pre-commercialization activities. The company is targeting an NDA submission in about one year and estimates a market opportunity of $700 million annually for XORLO.
“Our planned IND submission to the FDA next quarter is a defining step for the XRx-026 program,” said Allen Davidoff, Co-CEO of XORTX. “It reflects the strength of our prior clinical results and moves us closer to potentially offering gout patients a differentiated treatment option.”
For patients and investors alike, the implications are significant. Gout is a chronic disease with rising prevalence, and current treatments often fall short due to tolerability issues. If XORLO succeeds in clinical trials and gains FDA approval, it could offer a better-tolerated alternative, improving adherence and outcomes. XORTX’s progress, from manufacturing to regulatory strategy, signals that a new option may be on the horizon. As the company continues to advance its program, the details of its journey are being followed by outlets such as published on Benzinga, and further disclosures are available here. The original release can be viewed on www.newmediawire.com.
